- Home
- JL vs KALA Comparison
JL vs KALA Comparison
Compare JL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- KALA
- Stock Information
- Founded
- JL 1985
- KALA 2009
- Country
- JL Hong Kong
- KALA United States
- Employees
- JL N/A
- KALA N/A
- Industry
- JL
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- KALA Health Care
- Exchange
- JL NYSE
- KALA Nasdaq
- Market Cap
- JL 23.3M
- KALA 26.2M
- IPO Year
- JL 2024
- KALA 2017
- Fundamental
- Price
- JL $6.31
- KALA $7.14
- Analyst Decision
- JL
- KALA Strong Buy
- Analyst Count
- JL 0
- KALA 3
- Target Price
- JL N/A
- KALA $14.00
- AVG Volume (30 Days)
- JL 11.1K
- KALA 198.2K
- Earning Date
- JL 08-12-2025
- KALA 08-05-2025
- Dividend Yield
- JL N/A
- KALA N/A
- EPS Growth
- JL 207.45
- KALA N/A
- EPS
- JL 0.80
- KALA N/A
- Revenue
- JL $39,075,090.00
- KALA N/A
- Revenue This Year
- JL N/A
- KALA N/A
- Revenue Next Year
- JL N/A
- KALA N/A
- P/E Ratio
- JL $7.92
- KALA N/A
- Revenue Growth
- JL 37.69
- KALA N/A
- 52 Week Low
- JL $2.33
- KALA $2.92
- 52 Week High
- JL $13.41
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- JL 51.60
- KALA 59.52
- Support Level
- JL $6.11
- KALA $5.35
- Resistance Level
- JL $6.66
- KALA $8.49
- Average True Range (ATR)
- JL 0.32
- KALA 0.81
- MACD
- JL -0.07
- KALA 0.17
- Stochastic Oscillator
- JL 20.41
- KALA 57.01
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.